#United States #Class Action #Securities Fraud #Bensalem #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Over Securities Fraud Allegations

Capricor Therapeutics, Inc. (CAPR) is currently embroiled in legal troubles as its investors brace for potential recovery from significant losses. The Law Offices of Howard G. Smith have announced the opportunity for affected shareholders to lead a class action lawsuit, targeting alleged securities fraud that occurred between December 17, 2025, and July 26, 2026. Investors who suffered losses during this period are strongly encouraged to act before the lead plaintiff deadline on September 28, 2026.

Understanding the Allegations

The crux of the allegations revolves around claims that Capricor Therapeutics misled investors regarding the efficacy and approval prospects of Deramiocel, a treatment for Duchenne muscular dystrophy. Specifically, the complaint asserts that the company made untrue or exaggerated claims about its clinical trials and regulatory approvals. It points out several misleading statements, including:
1. The changes that Capricor allegedly made to the statistical analysis plan for clinical data, purportedly without prior agreement from the FDA.
2. The risk of non-approval by the FDA due to these changes, suggesting that the company’s statements lacked a basis in reality.
3. The impact that these inaccurate representations could have on the future of Deramiocel and its market performance.

These revelations have eroded investor confidence, prompting the call for legal action from shareholders who believe they were misled about the operational status of the company and the validity of its products.

Importance of Class Action Lawsuits

Class action lawsuits serve as a powerful tool for investors, especially those who may otherwise find it challenging to pursue legal action independently. They allow a group of individuals to combine their claims against a single entity, thus sharing legal resources and increasing the potential for a more favorable outcome. In this case, the investors who unite to challenge Capricor may find that their collective voice provides greater leverage against the company.

Howard G. Smith’s office is facilitating communication for investors to discuss their potential involvement in this class action. The firm is prepared to guide participants through the complexities of the litigation process and ensure their rights are adequately represented. Interested parties can reach the Law Offices of Howard G. Smith by email, phone, or through their website for further details and legal advice.

What Affected Shareholders Should Do

If you are an investor in Capricor Therapeutics and have faced financial losses resulting from the aforementioned events, it is crucial to understand your rights. You are not required to take any immediate action; however, it is advisable to consult with legal representation who can help you navigate your options. The deadline to join the class action lawsuit is approaching, so take the initiative to seek information and make informed decisions regarding your potential participation.

In conclusion, the situation surrounding Capricor Therapeutics serves as a stark reminder of the risks inherent in biotech investments. Shareholders should stay informed and proactive as developments emerge within this class action lawsuit against the company, as it could significantly impact their investments moving forward.